Increased events seen through three-year follow-up, but similar event rates observed between three and five years<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, May 24, 2023 (HealthDay News) — For patients undergoing percutaneous coronary intervention, first-generation bioresorbable vascular scaffolds (BVS) seem to be as safe as cobalt chromium everolimus-eluting stents (CoCr-EES) at five years, according to a study published online May 17 in the Journal of the American College of Cardiology.<\/em> The research was published to coincide with EuroPCR, the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held from May 14 to 17 in Paris.<\/p>\n Gregg W. Stone, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined long-term outcomes from the ABSORB IV trial, involving 2,604 patients at 147 sites, in which polymeric everolimus-eluting BVS implanted with improved technique demonstrated noninferior one-year outcomes compared with CoCr-EES.<\/p>\n The researchers found that at five years, target lesion failure occurred in 17.5 and 14.5 percent of patients assigned to BVS and CoCr-EES, respectively. Device thrombosis within five years occurred in 1.7 percent of BVS patients and 1.1 percent of CoCr-EES patients. Through three-year follow-up, event rates were slightly greater with BVS than CoCr-EES and were then similar between three and five years. Centrally adjudicated angina recurred within five years in 659 patients and 674 patients assigned to BVS and CoCr-EES, respectively (cumulative rates, 53.0 versus 53.3 percent).<\/p>\n “The early excess risk could likely be eliminated with an improved thinner next-generation scaffold and its implantation with intravascular imaging guidance, affording long-term restoration of the coronary artery to its original native state without a permanent implant,” Stone said in a statement.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Abbott, which funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n